Aurinia Pharmaceuticals AUPH Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's short- and long-term operating lease liabilities?
- Aurinia Pharmaceuticals (AUPH) reported short- and long-term operating lease liabilities of -$214K in Q1 2026.
- How has Aurinia Pharmaceuticals's short- and long-term operating lease liabilities changed year-over-year?
- Aurinia Pharmaceuticals's short- and long-term operating lease liabilities decreased by 9.7% year-over-year, from -$195K to -$214K.
- What is the long-term trend for Aurinia Pharmaceuticals's short- and long-term operating lease liabilities?
- Over 3 years (2022 to 2025), Aurinia Pharmaceuticals's short- and long-term operating lease liabilities has grown at a 7.1% compound annual growth rate (CAGR), from -$652K to -$802K.